Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand

Waranya Rattanavipapong, Chittawan Poonsiri (), Wanrudee Isaranuwatchai, Sopon Iamsirithaworn, Jutarat Apakupakul, Chaninan Sonthichai, Rungrueng Kitphati and Yot Teerawattananon
Additional contact information
Waranya Rattanavipapong: Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health
Chittawan Poonsiri: Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health
Wanrudee Isaranuwatchai: Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health
Sopon Iamsirithaworn: Department of Disease Control, Ministry of Public Health
Jutarat Apakupakul: Department of Disease Control, Ministry of Public Health
Chaninan Sonthichai: Department of Disease Control, Ministry of Public Health
Rungrueng Kitphati: Health Technical Office, Ministry of Public Health
Yot Teerawattananon: Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health

Applied Health Economics and Health Policy, 2023, vol. 21, issue 3, No 13, 522 pages

Abstract: Abstract Background and Aims The introduction of Coronavirus disease 2019 (COVID-19) vaccines urged all Thais to seek prevention of serious illness and death from COVID-19. However, immunocompromised individuals might not be able to achieve an efficient immune response from these vaccines. This study aimed to evaluate the cost-effectiveness and budget impact of introducing Evusheld (tixagevimab plus cilgavimab) for three patient groups—organ transplant, autoimmune disease, and dialysis patients, from the Thai government perspective. Methods A Markov decision model was developed to compare the use of Evusheld plus COVID-19 vaccines versus COVID-19 vaccines alone. The methodology followed the National HTA Guidelines of Thailand. Model input parameters were collected locally from retrospective data and from a literature review. Results Evusheld helped prevent COVID-19 infection, severe infection, and death in all three patient groups. Using the Thai threshold of 160,000 Thai Baht (THB) per quality-adjusted life year (QALY) gained, the only scenario found to be cost-effective was that of dialysis patients with inadequate immune response, with an incremental cost-effectiveness ratio (ICER) of 54,700 THB per QALY gained. To make a policy of Evusheld provision cost-effective in other groups, the price of Evusheld had to be lower (a reduction of 44–88% of its current price). The results of one-way sensitivity analysis indicated that the cost-effectiveness of Evusheld was sensitive to changes in the rate of infection, cost and efficacy of Evusheld, proportion of inadequate immune responses, and the probability of moving from a ‘recovered’ to ‘susceptible’ status. Conclusion Among three COVID-19-vaccinated immunocompromised patient populations, this study concluded that Evusheld was cost-effective for dialysis patients with inadequate immune response to the COVID-19 vaccine.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-023-00796-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:21:y:2023:i:3:d:10.1007_s40258-023-00796-7

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-023-00796-7

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().